FOXA1 and prostate cancer: For example, in in vitro models of prostate cancer, the BET inhibitor JQ1 interacts with FOXA1 and prevents it from repressing genes implicated in epithelial-to-mesenchymal transition, resulting in invasive phenotypes (69).